McKesson Just Raised Fiscal 2027 EPS Guidance to $45-and Pledged $5 Billion More Buybacks

McKesson paired a higher fiscal 2027 EPS outlook with a larger buyback

McKesson renewed the "too late?" debate by raising fiscal 2027 adjusted EPS to $44.20 to $45.00 and approving a $5.0 billion increase to the share repurchase program. The bullish read is straightforward: a large, cash-generative company is raising its outlook while expanding stock buybacks. The caution is that Q1 was mixed on the headline front-consolidated revenues of $105.4 billion increased 8%, adjusted earnings per diluted share of $9.93 increased 20%, but earnings per diluted share of $5.15 decreased $1.10.

Why investors are focused on the mix of signals

Last year McKesson generated $403.4 billion in revenue and $5.4 billion in free cash flow. That gives management room to do both at once: lift the full-year outlook and increase buybacks. The main risk is not weak execution so much as paying richer multiples before the market fully absorbs the follow-through.

The guidance increase matters because it sits alongside capital returns

McKesson raised fiscal 2027 adjusted EPS to $44.20 to $45.00 from $43.80 to $44.60. Management said that range indicates 13% to 15% growth compared with the prior year. In Q1, adjusted EPS also rose 20%, while revenue increased 8%, suggesting profits are improving at least partly through mix and execution rather than top-line growth alone.

Buybacks are adding to operating momentum

The repurchase authorization now stands at $7.7 billion, and McKesson also entered a $2.25 billion accelerated share repurchase program. That matters because earnings-per-share growth is coming from two levers at once: stronger operating performance and a potentially smaller share base.

That capital-return message also includes dividends. McKesson returned $2.6 billion to shareholders in Q1 and raised its quarterly dividend 15% to $0.94 per share.

The segment mix helps explain the leverage

McKesson operates through four segments, including U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International. Management linked the strong start to oncology and multispecialty and its biopharma services platform, while last year's outlook also emphasized high-growth and high-margin areas in Oncology and Biopharma Services. That points to a business where specialty and services mix can support better earnings quality than commodity distribution growth alone.

What would validate the setup from here

The next question is less about whether management can raise the guide once and more about whether the higher-margin mix continues to drive profit. Key things to watch:

• Continued strength in oncology and multispecialty and biopharma services
• Sustained dividend growth after the 15% to $0.94 per share increase
• Ongoing buyback execution under the $7.7 billion authorization
• Evidence that adjusted EPS strength is flowing more consistently into reported diluted EPS

If those signals hold, the combination of operating leverage and share reduction can keep supporting the stock. If the mix benefit fades or reported EPS again lags adjusted figures, investors are more likely to treat the outlook as fully priced rather than early.